APA (7th ed.) Citation

AP, S., TV, G., IV, B., ES, K., KB, K., AA, R., . . . EN, I. (2021). Molecular predictors of the outcome of paclitaxel plus carboplatin neoadjuvant therapy in high-grade serous ovarian cancer patients. Cancer chemotherapy and pharmacology, 88(3), 439. https://doi.org/10.1007/s00280-021-04301-6

Chicago Style (17th ed.) Citation

AP, Sokolenko, et al. "Molecular Predictors of the Outcome of Paclitaxel Plus Carboplatin Neoadjuvant Therapy in High-grade Serous Ovarian Cancer Patients." Cancer Chemotherapy and Pharmacology 88, no. 3 (2021): 439. https://doi.org/10.1007/s00280-021-04301-6.

MLA (9th ed.) Citation

AP, Sokolenko, et al. "Molecular Predictors of the Outcome of Paclitaxel Plus Carboplatin Neoadjuvant Therapy in High-grade Serous Ovarian Cancer Patients." Cancer Chemotherapy and Pharmacology, vol. 88, no. 3, 2021, p. 439, https://doi.org/10.1007/s00280-021-04301-6.